# Clinical Study on Third-line Treatment of Advanced Duodenal Adenocarcinoma by Fuquinitinib Combined With Sindillimab

> **NCT05810142** · — · NOT_YET_RECRUITING · sponsor: **RenJi Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Third-line Treatment
- Dvanced Duodenal Adenocarcinoma
- Furquinelone Combined With Sintilimab

## Interventions

- **DRUG:** furquimatinib and sintilimab

## Key facts

- **NCT ID:** NCT05810142
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-07-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05810142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05810142, "Clinical Study on Third-line Treatment of Advanced Duodenal Adenocarcinoma by Fuquinitinib Combined With Sindillimab". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05810142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*